WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment

Background: Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder defined by cytopenia and is associated with an increased risk of transformation to acute myeloid leukemia (AML). The outcome of MDS is poor, so alternative therapeutic approaches are needed to improve survival. The inhibition of the DNA damage response pathway, including poly (ADP-ribose) polymerase-1 (PARP-1), has been approved to treat several cancers. In addition, Wee1, a nuclear kinase, is overexpressed in many cancers. Therefore, a Wee1 Inhibitor combined with a PARP-1 inhibitor could inhibit the proliferation of MDS and AML.

Methods: We analyzed whether Wee1 was regulated in the progression of MDS and AML. We also evaluated the efficacy of MK-1775 (Wee1 Inhibitor) and talazoparib (PARP-1 inhibitor).

Results: PARP-1 expression was higher in the AML cells than in the MDS cells. However, Wee1 expression remained unchanged. MK-1775 or talazoparib alone inhibited MDS and AML cells after 72 h, and cellular cytotoxicity and Caspase 3/7 activity were increased. The combined use of MK-1775 and talazoparib produced superior efficacy than either drug alone and SKM-1 colony formation was reduced. Significant cell populations in the sub-G1 phase were found in the cell-cycle analyses. Additionally, γ-H2AX expression and Caspase 3 activity were increased. The combined treatment also changed the mitochondrial membrane potential.

Conclusions: The combination of a Wee1 Inhibitor and PARP-1 inhibitor had enhanced efficacy and is proposed as a new therapeutic option for patients with MDS or AML. Our findings have clinical implications for a potential novel therapeutic strategy for MDS and AML patients.

Cell proliferation; Myelodysplastic syndrome; PARP-1; WEE1.